Sinocelltech Group Ltd (688520) - Total Liabilities
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has total liabilities worth CN¥4.49 Billion CNY (≈ $657.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688520 cash flow conversion to assess how effectively this company generates cash.
Sinocelltech Group Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Sinocelltech Group Ltd's assets to evaluate the company's liquid asset resilience ratio.
Sinocelltech Group Ltd Competitors by Total Liabilities
The table below lists competitors of Sinocelltech Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
An Hui Wenergy Co Ltd
SHE:000543
|
China | CN¥42.96 Billion |
|
The Chefs Warehouse Inc
NASDAQ:CHEF
|
USA | $1.34 Billion |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
China | CN¥13.08 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $113.72 Million |
|
C Sun Manufacturing Ltd
TW:2467
|
Taiwan | NT$7.48 Billion |
|
American States Water Company
NYSE:AWR
|
USA | $1.65 Billion |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
China | CN¥2.92 Billion |
|
Newmark Group Inc
NASDAQ:NMRK
|
USA | $3.27 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Sinocelltech Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sinocelltech Group Ltd (688520) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinocelltech Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual total liabilities of Sinocelltech Group Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.15 Billion ≈ $460.81 Million |
-5.27% |
| 2023-12-31 | CN¥3.32 Billion ≈ $486.46 Million |
+11.63% |
| 2022-12-31 | CN¥2.98 Billion ≈ $435.78 Million |
+85.64% |
| 2021-12-31 | CN¥1.60 Billion ≈ $234.74 Million |
+49.21% |
| 2020-12-31 | CN¥1.08 Billion ≈ $157.33 Million |
+39.02% |
| 2019-12-31 | CN¥773.39 Million ≈ $113.17 Million |
+37.22% |
| 2018-12-31 | CN¥563.60 Million ≈ $82.47 Million |
+76.62% |
| 2017-12-31 | CN¥319.10 Million ≈ $46.69 Million |
-6.50% |
| 2016-12-31 | CN¥341.30 Million ≈ $49.94 Million |
-- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more